Health groups appeal European Patent Office decision to uphold Gilead’s patent on hepatitis C drug

The appeal – filed by six organisations – states that the EPO should revoke Gilead’s patent on key hepatitis C drug sofosbuvir because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.

MSF criticises pharma for dragging feet on developing HIV drugs for children.

As ministers and leaders from member countries gather in Singapore this week, Japan and South Korea continue to push India and the ten member states of ASEAN to agree to IP provisions that undermine generic competition.

MSF calls on Global Fund Board to make urgent changes to prevent drug stock-outs and quality issues.